Ironwood Pharmaceuticals — Q3 2026 Earnings Summary

Ironwood Pharmaceuticals raised its full-year 2026 financial guidance, projecting U.S. LINZESS net sales between $1.20 billion and $1.25 billion and total revenue between $485 million and $510 million. In the third quarter of 2026, the company reported $325 million in LINZESS U.S. net sales, resulting in a total revenue of $133 million and a record adjusted EBITDA of $98 million. The company is advancing the STARS-2 Phase 3 trial for its investigational drug apraglutide in short bowel syndrome and announced a leadership transition where Chief Commercial Officer Tammi Gaskins will become CEO on January 1, 2027.